Transcatheter aortic valve replacement (TAVI) is undoubtedly one of the most dramatic advancements in today's medical technology. The birth of this technology not only gives hope to many high-risk patients, but also creates a new situation in the treatment of cardiovascular disease. On April 16, 2002, French doctor Alain Cribier successfully performed the first TAVI operation on a 68-year-old female patient at Rouen University Hospital. This operation was not only a breakthrough in medical technology, but also a revolution in traditional heart surgery. A challenge.
"The birth of TAVI technology allows us to provide treatment for patients with severe aortic stenosis without opening the heart."
TAVI is designed for patients who cannot tolerate traditional thoracotomy, which is one of its greatest advantages. With the continuous development of technology, this surgery is gradually being used in a wider range of patient groups, especially those with intermediate risk. According to studies, the efficacy of TAVI is equivalent to that of traditional surgery. This means that more patients can have a chance to extend their lives through this minimally invasive surgery.
Although TAVI surgery does not require a long period of anesthesia and postoperative recovery like traditional surgery, it is not without risks. During the operation, the doctor needs to choose the most appropriate insertion method based on the specific conditions of the patient's heart, including transfemoral artery, transapical, transaortic and other routes.
"Currently, the choice of TAVI surgery depends on the patient's age, health and specific conditions of the heart."
Each access route has its advantages and disadvantages, and doctors will conduct a comprehensive evaluation before surgery to ensure the safety of the surgery. In addition, postoperative medical monitoring is equally critical. Patients need regular medical check-ups to ensure that their heart valves are functioning properly and to prevent possible infection risks. For most patients, the recovery period after surgery is relatively short, and most people can return to normal activities within a few weeks.
Although TAVI performs very well in reducing surgical mortality, it still has some potential complications that need to be noted, including major bleeding, renal insufficiency, and stroke. It is worth mentioning that studies have shown that approximately 3% of patients will experience stroke after TAVI, which is mainly caused by embolism or hemodynamic changes after surgery.
"Health care workers must closely monitor these potential complications to ensure successful surgery and reduce the risk of death."
Clinical studies have found that approximately 70% of TAVI patients show potential silent cerebral infarction on postoperative MRI. This phenomenon has attracted the attention of the medical community, but it is unclear whether its long-term effects will significantly reduce patients' quality of life.
With the continuous advancement of technology, the durability of TAVI technology is also gradually improving. Over the past few years, many new heart valves have been improved, significantly improving the success rate of the procedure. At the same time, for those patients who are younger than 75 years old and have a higher probability of survival, choosing traditional surgery may be more stable, because these patients face a higher risk of re-operation in the future.
Whether it is a breakthrough in medical technology or a story of patient recovery, the historical process of TAVI is like a wonderful documentary, showing the enterprising spirit of doctors and the infinite possibilities of technology. Starting from the successful case of the first operation, TAVI has changed the fate of many high-risk patients. In the future, how will this technology continue to develop and improve to better serve patients?